Mikael Dolsten, MD, PhD

Director

Mikael Dolsten, M.D., Ph.D., recently retired from Pfizer Inc after a 16-year tenure as chief scientific officer and president, worldwide research, development and medical. In that role, he led Pfizer’s global R&D organization, overseeing the advancement of over 36 medicines and vaccines through regulatory approval. Prior to joining Pfizer, Mikael held senior research and leadership positions at Wyeth Pharmaceuticals, Boehringer Ingelheim, AstraZeneca, Pharmacia, and Upjohn.

Mikael currently serves on the boards of directors of public companies Agilent Technologies, Inc. and Rocket Pharmaceuticals, Inc. He is chairman or board director for several private companies including Orbis Medicines, Orogen Therapeutics, Quarry Thera, ChAi Discovery, Enveda Bio, and Arbor Biotechnologies. Mikael is an advisor to financially oriented businesses groups such as Blackstone, GV (Google Ventures), Bain & Company, Sutter Hill Ventures, Canaan Partners, and Formation Bio. He has published over 160 scientific articles and book reviews, and holds an M.D. and a Ph.D. from Lund University, where he served as an adjunct professor.